액체생검 시장 규모, 점유율, 동향 분석 : 바이오마커별, 기술별, 시료 유형별, 용도별, 임상 용도별, 최종 용도별, 제품별, 지역별, 부문별 예측(2025-2030년)

Liquid Biopsy Market Growth & Trends:

The global liquid biopsy market size is expected to reach USD 22.88 billion by 2030, registering a CAGR of 11.54% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of cancer and the growing geriatric population are major drivers expected to fuel market growth. Furthermore, the use of technologically advanced devices for early detection of diseases is one of the key factors driving the market. In addition, the increasing preference for noninvasive treatment procedures will offer lucrative opportunities in the forecast period.

In recent years, cases of cancer have been rising tremendously and the trend is projected to remain the same in the foreseeable future. A significant shift in lifestyle has exposed the global population to this disorder and has resulted in oncogenic factors. For instance, as per the American Cancer Society, in 2022, the number of new cancer cases is expected to reach 1.9 million, leading to 609,360 deaths. Companies are focusing on expanding their business operations in the clinical liquid biopsy space.

For instance, in December 2021, Helio Health and Fulgent Genetics announced the launch of the former's HelioLiver, a new liquid biopsy test for early liver cancer detection. This liquid biopsy test combines serum protein markers and cell-free DNA methylation patterns. Additionally, new research studies are aiding the development of novel liquid biopsy techniques. For instance, in July 2022, the University of Central Florida announced the development of a novel liquid biopsy technique that facilitates early detection using biomarker identification for lung and breast cancer, making the monitoring of conditions easier.

The enhanced interest of players in liquid biopsy and the increasing rate of approval of new products are further accelerating market growth. Moreover, in the past several years, studies have shown a positive outcome of liquid biopsy platforms. Governments and various regulatory bodies have also shown interest in the area by promoting multiple breakthrough devices for the rapid development of this technology. With the high adoption of the technology by various companies, along with the support of government funding and initiatives, the market is expected to grow in the coming years.

Liquid Biopsy Market Report Highlights:

• Based on technology, the multi-gene-parallel analysis (NGS) segment led the market with the largest revenue share of 76.17% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period.
• Based on biomarker, the circulating tumor cells (CTC) biomarker segment led the market with the largest revenue share of 35.67% in 2024. The exosomes/microvesicles segment is anticipated to grow at the fastest CAGR of 13.82% over the forecast period.
• Based on application, the cancer segment led the market with the largest revenue share of 86.31% in 2024.The reproductive health segment is anticipated to grow at the fastest CAGR of 12.75% over the forecast period.
• Based on end use, the hospitals and laboratories segment led the market with the largest revenue share of 42.44% in 2024. The specialty clinics segment is anticipated to grow at the fastest CAGR of 12.16% over the forecast period.
• Based on clinical application, the therapy selection segment led the market with the largest revenue share of 33.69% in 2024.The early screening segment is expected to grow at the fastest CAGR of 12.38% over the forecast period.
• The instruments product segment dominated the market with the largest revenue share of 46.74% in 2024.The kits and reagents product segment is expected to grow at a significant CAGR during the forecast period.
• Based on sample type, the blood sample segment led the market with the largest revenue share of 71.44% in 2024 and is projected to maintain its dominance over the forecast period.
• North America dominated the liquid biopsy market with the largest revenue share of 51.15% in 2024.The liquid biopsy market in Asia Pacific is expected to grow at the fastest CAGR of 13.02% over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. List of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing prevalence of cancer
  • 3.4.2. Growing geriatric population
  • 3.4.3. Technological advancements
  • 3.4.4. Increasing preference for noninvasive treatment
• 3.5. Market Restraint Analysis
  • 3.5.1. Patent expiry of blockbuster drugs prescribed
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic and Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Type Business Analysis

• 4.1. Liquid Biopsy Market: Type Movement Analysis
• 4.2. Blood Sample
  • 4.2.1. Blood Sample Market, 2018 - 2030 (USD Million)
• 4.3. Others
  • 4.3.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. Biomarker Business Analysis

• 5.1. Liquid Biopsy Market: Biomarker Movement Analysis
• 5.2. Circulating Tumor Cells (CTCs)
  • 5.2.1. Circulating Tumor Cells (CTCs) Market, 2018 - 2030 (USD Million)
• 5.3. Circulating Tumor DNA (ctDNA)
  • 5.3.1. Circulating Tumor DNA (ctDNA) Market, 2018 - 2030 (USD Million)
• 5.4. Extracellular Vehicles (EVs)
  • 5.4.1. Extracellular Vehicles (EVs) Market, 2018 - 2030 (USD Million)
• 5.5. Others
  • 5.5.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Technology Business Analysis

• 6.1. Liquid Biopsy Market: Technology Movement Analysis
• 6.2. Multi-gene-parallel Analysis (NGS)
  • 6.2.1. Multi-gene-parallel Analysis (NGS) Market, 2018 - 2030 (USD Million)
• 6.3. Single Gene Analysis (PCR Microarrays)
  • 6.3.1. Single Gene Analysis (PCR Microarrays) Market, 2018 - 2030 (USD Million)

Chapter 7. Application Business Analysis

• 7.1. Liquid Biopsy Market: Application Movement Analysis
• 7.2. Cancer
  • 7.2.1. Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.1. Lung Cancer
      • 7.2.1.1.1. Lung Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.2. Prostate Cancer
      • 7.2.1.2.1. Prostate Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.3. Breast Cancer
      • 7.2.1.3.1. Breast Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.4. Colorectal Cancer
      • 7.2.1.4.1. Colorectal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.5. Leukemia
      • 7.2.1.5.1. Leukemia Market, 2018 - 2030 (USD Million)
    • 7.2.1.6. Gastrointestinal Cancer
      • 7.2.1.6.1. Gastrointestinal Cancer Market, 2018 - 2030 (USD Million)
    • 7.2.1.7. Others
      • 7.2.1.7.1. Others Market, 2018 - 2030 (USD Million)
• 7.3. Reproductive Health
  • 7.3.1. Reproductive Health Market, 2018 - 2030 (USD Million)
• 7.4. Others
  • 7.4.1. Others Market, 2018 - 2030 (USD Million)

Chapter 8. End-Use Business Analysis

• 8.1. Liquid Biopsy Market: End-Use Movement Analysis
• 8.2. Hospitals and Laboratories
  • 8.2.1. Hospitals and Laboratories Market, 2018 - 2030 (USD Million)
• 8.3. Specialty Clinics
  • 8.3.1. Specialty Clinics Market, 2018 - 2030 (USD Million)
• 8.4. Academic and Research Centers
  • 8.4.1. Academic and Research Centers Market, 2018 - 2030 (USD Million)
• 8.5. Others
  • 8.5.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 9. Clinical Application Business Analysis

• 9.1. Liquid Biopsy Market: Clinical Application Movement Analysis
• 9.2. Therapy Selection
  • 9.2.1. Therapy Selection Market, 2018 - 2030 (USD Million)
• 9.3. Treatment Monitoring
  • 9.3.1. Treatment Monitoring Market, 2018 - 2030 (USD Million)
• 9.4. Early Cancer Screening
  • 9.4.1. Early Cancer Screening Market, 2018 - 2030 (USD Million)
• 9.5. Recurrence Monitoring
  • 9.5.1. Recurrence Monitoring Market, 2018 - 2030 (USD Million)
• 9.6. Others
  • 9.6.1. Others Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 10. Product Business Analysis

• 10.1. Liquid Biopsy Market: Product Movement Analysis
• 10.2. Instruments
  • 10.2.1. Instruments Market, 2018 - 2030 (USD Million)
• 10.3. Consumables Kits, and Reagents
  • 10.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Million)
• 10.4. Software and Services
  • 10.4.1. Software and Services Market, 2018 - 2030 (USD Million)

Chapter 11. Regional Business Analysis

• 11.1. Liquid Biopsy Market Share, By Region, 2024 & 2030
• 11.2. North America
  • 11.2.1. North America Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.2.2. U.S.
    • 11.2.2.1. Key Country Dynamics
    • 11.2.2.2. Target Disease Prevalence
    • 11.2.2.3. Competitive Scenario
    • 11.2.2.4. Regulatory Framework
    • 11.2.2.5. Reimbursement Scenario
    • 11.2.2.6. U.S. Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.2.3. Canada
    • 11.2.3.1. Key Country Dynamics
    • 11.2.3.2. Target Disease Prevalence
    • 11.2.3.3. Competitive Scenario
    • 11.2.3.4. Regulatory Framework
    • 11.2.3.5. Reimbursement Scenario
    • 11.2.3.6. Canada Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.3. Europe
  • 11.3.1. Europe Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.2. Germany
    • 11.3.2.1. Key Country Dynamics
    • 11.3.2.2. Target Disease Prevalence
    • 11.3.2.3. Competitive Scenario
    • 11.3.2.4. Regulatory Framework
    • 11.3.2.5. Reimbursement Scenario
    • 11.3.2.6. Germany Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.3. UK
    • 11.3.3.1. Key Country Dynamics
    • 11.3.3.2. Target Disease Prevalence
    • 11.3.3.3. Competitive Scenario
    • 11.3.3.4. Regulatory Framework
    • 11.3.3.5. Reimbursement Scenario
    • 11.3.3.6. UK Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.4. France
    • 11.3.4.1. Key Country Dynamics
    • 11.3.4.2. Target Disease Prevalence
    • 11.3.4.3. Competitive Scenario
    • 11.3.4.4. Regulatory Framework
    • 11.3.4.5. Reimbursement Scenario
    • 11.3.4.6. France Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.5. Italy
    • 11.3.5.1. Key Country Dynamics
    • 11.3.5.2. Target Disease Prevalence
    • 11.3.5.3. Competitive Scenario
    • 11.3.5.4. Regulatory Framework
    • 11.3.5.5. Reimbursement Scenario
    • 11.3.5.6. Italy Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.6. Spain
    • 11.3.6.1. Key Country Dynamics
    • 11.3.6.2. Target Disease Prevalence
    • 11.3.6.3. Competitive Scenario
    • 11.3.6.4. Regulatory Framework
    • 11.3.6.5. Reimbursement Scenario
    • 11.3.6.6. Spain Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.7. Denmark
    • 11.3.7.1. Key Country Dynamics
    • 11.3.7.2. Target Disease Prevalence
    • 11.3.7.3. Competitive Scenario
    • 11.3.7.4. Regulatory Framework
    • 11.3.7.5. Reimbursement Scenario
    • 11.3.7.6. Denmark Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.8. Sweden
    • 11.3.8.1. Key Country Dynamics
    • 11.3.8.2. Target Disease Prevalence
    • 11.3.8.3. Competitive Scenario
    • 11.3.8.4. Regulatory Framework
    • 11.3.8.5. Reimbursement Scenario
    • 11.3.8.6. Sweden Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.3.9. Norway
    • 11.3.9.1. Key Country Dynamics
    • 11.3.9.2. Target Disease Prevalence
    • 11.3.9.3. Competitive Scenario
    • 11.3.9.4. Regulatory Framework
    • 11.3.9.5. Reimbursement Scenario
    • 11.3.9.6. Norway Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.4. Asia Pacific
  • 11.4.1. Asia Pacific Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.2. Japan
    • 11.4.2.1. Key Country Dynamics
    • 11.4.2.2. Target Disease Prevalence
    • 11.4.2.3. Competitive Scenario
    • 11.4.2.4. Regulatory Framework
    • 11.4.2.5. Reimbursement Scenario
    • 11.4.2.6. Japan Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.3. China
    • 11.4.3.1. Key Country Dynamics
    • 11.4.3.2. Target Disease Prevalence
    • 11.4.3.3. Competitive Scenario
    • 11.4.3.4. Regulatory Framework
    • 11.4.3.5. Reimbursement Scenario
    • 11.4.3.6. China Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.4. India
    • 11.4.4.1. Key Country Dynamics
    • 11.4.4.2. Target Disease Prevalence
    • 11.4.4.3. Competitive Scenario
    • 11.4.4.4. Regulatory Framework
    • 11.4.4.5. Reimbursement Scenario
    • 11.4.4.6. India Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.5. South Korea
    • 11.4.5.1. Key Country Dynamics
    • 11.4.5.2. Target Disease Prevalence
    • 11.4.5.3. Competitive Scenario
    • 11.4.5.4. Regulatory Framework
    • 11.4.5.5. Reimbursement Scenario
    • 11.4.5.6. South Korea Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.6. Australia
    • 11.4.6.1. Key Country Dynamics
    • 11.4.6.2. Target Disease Prevalence
    • 11.4.6.3. Competitive Scenario
    • 11.4.6.4. Regulatory Framework
    • 11.4.6.5. Reimbursement Scenario
    • 11.4.6.6. Australia Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.4.7. Thailand
    • 11.4.7.1. Key Country Dynamics
    • 11.4.7.2. Target Disease Prevalence
    • 11.4.7.3. Competitive Scenario
    • 11.4.7.4. Regulatory Framework
    • 11.4.7.5. Reimbursement Scenario
    • 11.4.7.6. Thailand Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.5. Latin America
  • 11.5.1. Latin America Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.2. Brazil
    • 11.5.2.1. Key Country Dynamics
    • 11.5.2.2. Target Disease Prevalence
    • 11.5.2.3. Competitive Scenario
    • 11.5.2.4. Regulatory Framework
    • 11.5.2.5. Reimbursement Scenario
    • 11.5.2.6. Brazil Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.3. Mexico
    • 11.5.3.1. Key Country Dynamics
    • 11.5.3.2. Target Disease Prevalence
    • 11.5.3.3. Competitive Scenario
    • 11.5.3.4. Regulatory Framework
    • 11.5.3.5. Reimbursement Scenario
    • 11.5.3.6. Mexico Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.5.4. Argentina
    • 11.5.4.1. Key Country Dynamics
    • 11.5.4.2. Target Disease Prevalence
    • 11.5.4.3. Competitive Scenario
    • 11.5.4.4. Regulatory Framework
    • 11.5.4.5. Reimbursement Scenario
    • 11.5.4.6. Argentina Liquid biopsy market, 2018 - 2030 (USD Million)
• 11.6. MEA
  • 11.6.1. MEA Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.2. South Africa
    • 11.6.2.1. Key Country Dynamics
    • 11.6.2.2. Target Disease Prevalence
    • 11.6.2.3. Competitive Scenario
    • 11.6.2.4. Regulatory Framework
    • 11.6.2.5. Reimbursement Scenario
    • 11.6.2.6. South Africa Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.3. Saudi Arabia
    • 11.6.3.1. Key Country Dynamics
    • 11.6.3.2. Target Disease Prevalence
    • 11.6.3.3. Competitive Scenario
    • 11.6.3.4. Regulatory Framework
    • 11.6.3.5. Reimbursement Scenario
    • 11.6.3.6. Saudi Arabia Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.4. UAE
    • 11.6.4.1. Key Country Dynamics
    • 11.6.4.2. Target Disease Prevalence
    • 11.6.4.3. Competitive Scenario
    • 11.6.4.4. Regulatory Framework
    • 11.6.4.5. Reimbursement Scenario
    • 11.6.4.6. UAE Liquid biopsy market, 2018 - 2030 (USD Million)
  • 11.6.5. Kuwait
    • 11.6.5.1. Key Country Dynamics
    • 11.6.5.2. Target Disease Prevalence
    • 11.6.5.3. Competitive Scenario
    • 11.6.5.4. Regulatory Framework
    • 11.6.5.5. Reimbursement Scenario
    • 11.6.5.6. Kuwait Liquid biopsy market, 2018 - 2030 (USD Million)

Chapter 12. Competitive Landscape

• 12.1. Participant's overview
• 12.2. Financial performance
• 12.3. Participant categorization
  • 12.3.1. Market Leaders
  • 12.3.2. Liquid Biopsy Market Share Analysis, 2024
  • 12.3.3. Company Profiles
    • 12.3.3.1. ANGLE plc
      • 12.3.3.1.1. Company Overview
      • 12.3.3.1.2. Financial Performance
      • 12.3.3.1.3. Product Benchmarking
      • 12.3.3.1.4. Strategic Initiatives
    • 12.3.3.2. Oncimmune Holdings PLC
      • 12.3.3.2.1. Company Overview
      • 12.3.3.2.2. Financial Performance
      • 12.3.3.2.3. Product Benchmarking
      • 12.3.3.2.4. Strategic Initiatives
    • 12.3.3.3. Guardant Health
      • 12.3.3.3.1. Company Overview
      • 12.3.3.3.2. Financial Performance
      • 12.3.3.3.3. Product Benchmarking
      • 12.3.3.3.4. Strategic Initiatives
    • 12.3.3.4. Myriad Genetics, Inc.
      • 12.3.3.4.1. Company Overview
      • 12.3.3.4.2. Financial Performance
      • 12.3.3.4.3. Product Benchmarking
      • 12.3.3.4.4. Strategic Initiatives
    • 12.3.3.5. Biocept, Inc.
      • 12.3.3.5.1. Company Overview
      • 12.3.3.5.2. Financial Performance
      • 12.3.3.5.3. Product Benchmarking
      • 12.3.3.5.4. Strategic Initiatives
    • 12.3.3.6. Lucence Health Inc.
      • 12.3.3.6.1. Company Overview
      • 12.3.3.6.2. Financial Performance
      • 12.3.3.6.3. Product Benchmarking
      • 12.3.3.6.4. Strategic Initiatives
    • 12.3.3.7. Freenome Holdings, Inc.
      • 12.3.3.7.1. Company Overview
      • 12.3.3.7.2. Financial Performance
      • 12.3.3.7.3. Product Benchmarking
      • 12.3.3.7.4. Strategic Initiatives
    • 12.3.3.8. F. Hoffmann-La Roche Ltd.
      • 12.3.3.8.1. Company Overview
      • 12.3.3.8.2. Financial Performance
      • 12.3.3.8.3. Product Benchmarking
      • 12.3.3.8.4. Strategic Initiatives
    • 12.3.3.9. QIAGEN
      • 12.3.3.9.1. Company Overview
      • 12.3.3.9.2. Financial Performance
      • 12.3.3.9.3. Product Benchmarking
      • 12.3.3.9.4. Strategic Initiatives
    • 12.3.3.10. Illumina, Inc.
      • 12.3.3.10.1. Company Overview
      • 12.3.3.10.2. Financial Performance
      • 12.3.3.10.3. Product Benchmarking
      • 12.3.3.10.4. Strategic Initiatives
    • 12.3.3.11. Thermo Fisher Scientific, Inc.
      • 12.3.3.11.1. Company Overview
      • 12.3.3.11.2. Financial Performance
      • 12.3.3.11.3. Product Benchmarking
      • 12.3.3.11.4. Strategic Initiatives
    • 12.3.3.12. Epigenomics AG
      • 12.3.3.12.1. Company Overview
      • 12.3.3.12.2. Financial Performance
      • 12.3.3.12.3. Product Benchmarking
      • 12.3.3.12.4. Strategic Initiatives
  • 12.3.4. Strategy Mapping
    • 12.3.4.1. Expansion
    • 12.3.4.2. Acquisition
    • 12.3.4.3. Collaborations
    • 12.3.4.4. Disease Type/Drug Class Launch
    • 12.3.4.5. Partnerships
    • 12.3.4.6. Others